7-chloro-1,3-dimethyl-5-phenyl 1H-pyrazolo[4,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7-chloro-1,3-dimethyl-5-phenyl 1H-pyrazolo[4,3-d]pyrimidine
• 英文别名: 7-chloro-1,3-dimethyl-5-phenylpyrazolo[4,3-d]pyrimidine
• 化学式: C₁₃H₁₁ClN₄
• 分子量: 258.71
• InChiKey: UIFIEFKMOAASOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-chloro-1,3-dimethyl-5-phenyl 1H-pyrazolo[4,3-d]pyrimidine 在 三乙胺 、 sodium iodide 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 1,3,8-Trimethyl-5-phenyl-7,8-dihydro-1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidine
  参考文献：
  名称：

  Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines

  摘要：

  The synthesis of a series of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines is reported along with the effects of these compounds in preclinical tests for antipsychotic activity. Certain of these compounds displayed antipsychotic-like effects in conditioned avoidance tests, but unlike currently used antipsychotic drugs, they did not have affinity for brain dopamine receptors. These compounds also did not cause dystonias predictive of extrapyramidal side effects in monkeys at doses that produced behavioral effects. On the basis of this unique biological profile, a member of this series 7,8-dihydro-8-ethyl-1,3,5-trimethyl-1H-imidao[1,2-c]pyrazol[3,4-e] pyrimidine (19, CI-943), has been selected for clinical evaluation as an antipsychotic agent.

  DOI：

  10.1021/jm00397a032
• 作为产物：
  描述：

  1,3-dimethyl-5-phenylpyrazolo<4,3-d>pyrimidin-7-one 生成 7-chloro-1,3-dimethyl-5-phenyl 1H-pyrazolo[4,3-d]pyrimidine
  参考文献：
  名称：

  DEWALD, HORACE A.;BEESON, NICHOLAS W.;HERSHENSON, FRED M.;WISE, LAWRENCE +, J. MED. CHEM., 31,(1988) N 2, 454-461

  摘要：

  DOI：

文献信息

• Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
  申请人：Pal Manojit

  公开号：US20060128729A1

  公开（公告）日：2006-06-15

  The present invention provides, among other things, new bicyclo heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating a variety of conditions and disease states associated with, for example, cellular proliferation, inflammation, glycosidase expression, or the low expression of Perlecan.

  本发明提供了新的双环杂环化合物，包括这些杂环化合物的组合物，制备这些杂环化合物的方法，以及利用这些杂环化合物治疗与细胞增殖、炎症、糖苷酶表达或Perlecan低表达等多种疾病状态相关的方法。
• DEWALD, HORACE A.;BEESON, NICHOLAS W.;HERSHENSON, FRED M.;WISE, LAWRENCE +, J. MED. CHEM., 31,(1988) N 2, 454-461
  作者：DEWALD, HORACE A.、BEESON, NICHOLAS W.、HERSHENSON, FRED M.、WISE, LAWRENCE +

  DOI：——

  日期：——
• NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
  申请人：Reddy US Therapeutics, Inc.

  公开号：EP1814885A2

  公开（公告）日：2007-08-08
• [EN] NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES BICYCLIQUES HETEROCYCLIQUES, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS LES CONTENANT
  申请人：REDDY US THERAPEUTICS INC

  公开号：WO2006073610A2

  公开（公告）日：2006-07-13

  (EN) The present invention provides, among other things, new bicyclo heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating a variety of conditions and disease states associated with, for example, cellular proliferation, inflammation, glycosidase expression, or the low expression of Perlecan.(FR) La présente invention a trait, entre autres, à de nouveaux composés bicycliques hétérocycliques, à des compositions comportant ces composés bicycliques hétérocycliques, à des procédés de fabrication des composés bicycliques hétérocycliques, et à des procédés d'utilisation de ces composés bicycliques hétérocycliques pour le traitement d'une variété de conditions et d'états morbides associés, par exemple, à la prolifération cellulaire, à l'inflammation, à l'expression de glycosidase, ou la faible expression de perlecan.
• Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
  作者：Horace A. DeWald、Nicholas W. Beeson、Fred M. Hershenson、Lawrence D. Wise、David A. Downs、Thomas G. Heffner、Linda L. Coughenour、Thomas A. Pugsley

  DOI：10.1021/jm00397a032

  日期：1988.2

  The synthesis of a series of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines is reported along with the effects of these compounds in preclinical tests for antipsychotic activity. Certain of these compounds displayed antipsychotic-like effects in conditioned avoidance tests, but unlike currently used antipsychotic drugs, they did not have affinity for brain dopamine receptors. These compounds also did not cause dystonias predictive of extrapyramidal side effects in monkeys at doses that produced behavioral effects. On the basis of this unique biological profile, a member of this series 7,8-dihydro-8-ethyl-1,3,5-trimethyl-1H-imidao[1,2-c]pyrazol[3,4-e] pyrimidine (19, CI-943), has been selected for clinical evaluation as an antipsychotic agent.